Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

About this update from Helix Biopharma Corp.

(via TheNewswire)   Vancouver, British Columbia –TheNewswire -3 June, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures of the Company (each, a “Convertible Debenture”). The Company issued 3,673 Convertible Debentures for aggregate gross proceeds of C$3,673,000 pursuant to the Offering.The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement (the “Maturity Date”). Each Convertible Debenture will bear interest at 25.00% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the Maturity Date, the outstanding principal amount of the Convertible Debentures may be convertible by the holder on the Maturity Date into common shares in the capital of the Company (each, a “Share”) at a price of C$1.42 per Share, being the market price of the Shares as of the price reservation date, less the permitted 20% discount in accordance with TSX policies (the “Conversion Price”). If the Convertible Debentures are not repaid on or prior to the Maturity Date, any accrued but unpaid interest of the Convertible Debentures may be convertible by the holder on the Maturity Date into Shares at a conversion price of the greater of: (i) the Conversion Price; and (ii) the volume weighted average trading price of the Shares listed on TSX during the five (5) trading days immediately preceding the relevant date, less the TSX permitted discount (the “Interest Conversion Price”).The proceeds from the Offering are expected to be used for general working capital purposes as well as advancement of the Company’s drug development programs. No finder’s fees were paid in connection with the Offering.The Convertible Debentures and any Shares issuable thereunder are subject to a statutory four-month hold period commencing on the closing date of the Offering.   About Helix BioPharma Corp.Helix is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumo...

View stock analysis, news, and events for Helix Biopharma Corp.